IL17A and COVID-19: In the adults group, there was no significant difference in the rate of COVID-19 hospitalization (RR: 1.20; 95% CI: 0.42-3.39; P = 0.74) between the patients with psoriasis receiving IL-17 inhibitors and those receiving non-biologics.